P—Peptide library
Investigational peptides in clinical trials
Investigational peptides are being tested in registered human clinical trials but are not yet approved. Results can change quickly, so each profile links to trial registries and the most recent approved news items covering readouts and regulatory filings.
4 peptides
| Name | Type | Compounding | Categories | Evidence level | Ev. vs. Hype | Momentum | WADA | Reviewed | + |
|---|---|---|---|---|---|---|---|---|---|
| Cagrilintide | Investigational | Trial use only | Metabolic / GLP-1 | Human trials ongoing | Evidence Hype | Rising | Prohibited | 2026-10-30 | |
| CagriSema Cagrilintide + semaglutide | Investigational | Not allowed (blends excluded) | Metabolic / GLP-1 | Human trials ongoing | Evidence Hype | Watch | Prohibited | 2026-10-30 | |
| LL-37 | Investigational | Off Category 2, review pending | Immune | Small/early human studies | Evidence Hype | Watch | Verify | 2026-10-30 | |
| Retatrutide LY3437943 | Investigational | Trial use only | Metabolic / GLP-1 | Human trials ongoing | Evidence Hype | Rising | Prohibited | 2026-10-30 |
Information only — not medical advice. Browse and filter the full peptide library.